Recherches "plusieurs pathologies" CIRCA-HPV (IC 2017-01) Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses. Paris, Saint-Cloud BRUNO BUECHER
Appareil pulmonaire PACT-01 Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer. Paris, Saint-Cloud CATHERINE DANIEL, MARIE ANGE MASSIANI
Hématologie Lymphome non Hodgkinien M20-621 A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in;Combination with R-CHOP Compared to R-CHOP in Subjects with New Diagnosed Diffuse Large B-Cell;Lymphoma (DLBCL). Saint-Cloud
Hématologie Lymphome non Hodgkinien PRT2527-02 A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies. Saint-Cloud
Appareil pulmonaire TAS6417-201 An Open-Label, Phase 2b, Global Multicenter Cohort Trial to;Assess the Safety and Efficacy of Zipalertinib in Patients;with Locally Advanced or Metastatic Non-Small Cell Lung;Cancer with Exon 20 Insertion and Uncommon/Single or;Compound Epidermal Growth Factor Receptor Mutations. Paris NICOLAS GIRARD
Appareil Digestif DS8201-A-U207 DESTINY CRC02 A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02) Saint-Cloud
Appareil pulmonaire REAL MOOV LUNG Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG Paris, Saint-Cloud NICOLAS GIRARD, NICOLAS GIRARD
Recherches "plusieurs pathologies" REGOMUNE A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Saint-Cloud SEGOLENE HESCOT
Sein métastatique RH+ SERENA-6 D8534C00001 A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, ETIENNE BRAIN
Recherches "plusieurs pathologies" MOST Plus My Own Specific Treatment : A two-period, multicenter, randomized, open-label, phase II study evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with progressive locally-advanced or metastatic solid tumors Paris CHRISTOPHE LE TOURNEAU